Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active | |||
| Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Active | ||
| Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
| Remsima | infliximab | Crohn’s disease | Active | |||
| Remsima | infliximab | Ulcerative Colitis | Active | |||
| TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
| TBD | Cabozantinib | Withdrawn | ||||
| Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn |
Last Updated : April 28, 2024